CSL Ltd. is a biopharmaceutical company, which engages in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.
Company profile
Ticker
CSLLY, CMXHF
Exchange
Website
CEO
Paul Roger Perreault
Employees
Location
SEC CIK
CSLLY stock data
Latest filings (excl ownership)
F-6EF
Automatic registration for ADRs (foreign)
21 Jun 22
EFFECT
Notice of effectiveness
9 Jun 14
F-6
Registration for ADRs (foreign)
28 May 14
F-6EF
Automatic registration for ADRs (foreign)
4 Aug 11
F-6EF
Automatic registration for ADRs (foreign)
17 Jun 10
F-6EF
Automatic registration for ADRs (foreign)
4 Nov 08
F-6EF
Automatic registration for ADRs (foreign)
15 Oct 08
REGDEX
Notice of sale of securities
22 Dec 03
Transcripts
Latest ownership filings
Institutional ownership, Q2 2022
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 832.59 mm |
Total shares | 4.50 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Paradigm Asset Management | 4.50 k | $832.59 mm |
Press releases
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
28 Mar 24
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
19 Mar 24
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
23 Feb 24
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
23 Feb 24
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
12 Feb 24